Roche has signed a definitive merger agreement to acquire US-based biotechnology firm Promedior...
- UCB acquires Ra Pharma for $2.1bn to enrich its rare disease portfolio
- Pfizer licenses Akcea’s ANTPTL3-targetting drug for $250m
- Vertex-Semma $950m acquisition: bringing diabetes into the pipeline
- Takeda-Shire deal: the strategy behind Japan’s largest foreign acquisition
- Boehringer acquires AMAL Therapeutics for $366m
Sarepta and StrideBio sign gene therapy development deal
Sarepta Therapeutics has partnered with StrideBio for the development of in-vivo adeno-associated viral (AAV) based therapies for up to eight targets of the central nervous system (CNS) and neuromuscular conditions.
Bayer to invest $100m for alliance with Dewpoint Therapeutics
Bayer has entered an option, research and licence agreement valued at approximately $100m with Dewpoint Therapeutics to develop therapies for cardiovascular and gynaecological conditions.
Skyhawk and Celgene expand alliance to identify new drug targets
Skyhawk Therapeutics has formed a second alliance with an affiliate of Celgene to identify drug targets in autoimmune diseases, oncology and immuno-oncology.
Vaximm partners with NEC on neoantigen cancer vaccines
Biotech company Vaximm has partnered with technologies provider NEC Corporation to develop personalised neoantigen cancer vaccines.
Newpharma collaborates with Ingenico for e-payments
Belgian online pharmacy firm Newpharma has partnered with UK-based payments company Ingenico Group to enable secure payments for pharmaceutical buyers.
Regeneron and Vyriad to develop oncolytic virus therapies
Regeneron Pharmaceuticals has formed a five-year alliance with Vyriad for the development of oncolytic virus-based treatments for cancer.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.